Macular Dystrophy Clinical Trials

1 recruiting

Macular Dystrophy Trials at a Glance

8 actively recruiting trials for macular dystrophy are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 1 with 2 trials, with the heaviest enrollment activity in Dallas, Paris, and Irvine. Lead sponsors running macular dystrophy studies include Ray Therapeutics, Inc., Columbia University, and Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts.

Browse macular dystrophy trials by phase

Treatments under study

About Macular Dystrophy Clinical Trials

Looking for clinical trials for Macular Dystrophy? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Macular Dystrophy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Macular Dystrophy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting

Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4

Stargardt-Like Macular Dystrophy
National Eye Institute (NEI)25 enrolled1 locationNCT04591483
Recruiting

A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults

Stargardt DiseaseStargardt Macular Dystrophy
Astellas Pharma Global Development, Inc.90 enrolled3 locationsNCT07425574
Recruiting

Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)

Retinitis PigmentosaStargardt DiseaseStargardt Macular Dystrophy
Ray Therapeutics, Inc.25 enrolled1 locationNCT07502664
Recruiting
Phase 1Phase 2

Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)

ARBBVMDAutosomal-Dominant Bestrophinopathy+1 more
Opus Genetics, Inc10 enrolled4 locationsNCT07185256
Recruiting
Not Applicable

High Resolution, High-speed Multimodal Ophthalmic Imaging

HypertensionStrokeDiabetes+12 more
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts1,200 enrolled1 locationNCT04129021
Recruiting

Study of BEST1 Vitelliform Macular Dystrophy

Retinitis PigmentosaBest Vitelliform Macular Dystrophy
Columbia University52 enrolled3 locationsNCT05809635
Recruiting
Phase 1Phase 2

A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)

Stargardt DiseaseStargardt Macular DystrophyStargardt Macular Degeneration
Splice Bio57 enrolled5 locationsNCT06942572
Recruiting

Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration

Retinitis PigmentosaStargardt DiseaseRetinal Dystrophies+4 more
Ray Therapeutics, Inc.120 enrolled1 locationNCT06375239